Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Books » Medicine » Neurologic Disorders » Perspectives on Alzheimer's Disease Chapters » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Distributed Wind Energy Generation
$73.80
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Mild Cognitive Impairment: An Overview (pp. 103-113)
Tell A Friend
 
Tell someone you know about this product.
Mild Cognitive Impairment: An Overview (pp. 103-113) $100.00
Authors:  (M.S. Henry, D. Craig, J.A. Johnston, A.P. Passmore and B. McGuinness)
Abstract:
In an ageing population with a projected large increase in the burden of Alzheimer‘s disease (AD) on patients, carers and health care provision, there has recently been great interest in the concept of identifying those high-risk individuals in the area between normal cognition and dementia for whom early treatment may be beneficial in slowing or even halting progression of cognitive decline.
Mild cognitive impairment (MCI) is a syndrome defined as cognitive decline greater than expected for an individual‘s age and education level, but with preserved activities of daily living. Studies have confirmed an increased rate of progression to dementia in patients diagnosed with MCI (approximately 12% per year), with particular interest in the subtype of amnestic MCI (a-MCI) as a precursor to AD. Indeed some authors have described the clinical phenotype of amnestic MCI as mirroring that of fully expressed AD, only reflecting a milder stage.
Diagnostic testing and elucidation of early disease markers are important evolving concepts in the field of MCI research. Neuroimaging studies with MRI have shown characteristic patterns of atrophy, especially in medial temporal lobes, and white matter changes in MCI patients. Metabolic imaging with positron emission tomography (PET) is a promising modality for detection of functional abnormalities. Cerebrospinal fluid biomarkers such as beta-amyloid and tau may help to identify those patients at risk of decline from MCI to AD. Other studies have associated severity of episodic memory deficits and neuropsychiatric symptoms with progression to dementia.
MCI, however, is a heterogeneous condition which presents problems with respect to diagnosis and study variability. We discuss current thinking regarding the aetiology, diagnostic criteria and sub-typing of this syndrome. 


Available Options:
Version:
This Item Is Currently Unavailable.
Special Focus Titles
01.Peter Singer’s Ethics: A Critical Appraisal
02.Sexism: Past, Present and Future Perspectives
03.Body and Politics: Elite Disability Sport in China
04.Childhood and Adolescence: Tribute to Emanuel Chigier, 1928-2017
05.Renal Replacement Therapy: Controversies and Future Trends
06.Food-Drug Interactions: Pharmacokinetics, Prevention and Potential Side Effects
07.Terrorism and Violence in Islamic History and Theological Responses to the Arguments of Terrorists
08.International Event Management: Bridging the Gap between Theory and Practice
09.The Sino-Indian Border War and the Foreign Policies of China and India (1950-1965)
10.Tsunamis: Detection, Risk Assessment and Crisis Management
11.Sediment Watch: Monitoring, Ecological Risk Assessment and Environmental Management
12.Self-Regulated Learners: Strategies, Performance, and Individual Differences

Nova Science Publishers
© Copyright 2004 - 2018

Mild Cognitive Impairment: An Overview (pp. 103-113)